a d v a n c i n g i n n o v a t i o n i n h e a l t h c a r e partners...
TRANSCRIPT
![Page 1: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/1.jpg)
A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E
Partners Innovation Fund
Partners HealthCare
July 2017
![Page 2: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/2.jpg)
P A R T N E R S I N N O V A T I O N F U N DIn Brief
Capitalization $165M fund
$100 million core fund capitalized by MGH and BWH
$65 million strategic fund capitalized by pharma and other strategic investors
Focus Medical innovations discovered and developed at Partners institutions
Strategy Capital should accelerate breakthrough technologies in healthcare
![Page 3: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/3.jpg)
Experienced innovators, executives, entrepreneurs, and investors
Deep scientific domain expertise
Established track record of invention, new venture conception, and company building
Proven value creation
P I F I N V E S T M E N T T E A M
Meredith Fisher, PhDPartner
Life Science Investor & Scientist
Director, Bracebridge Capital
Sr. Director of Tech & Bus Devel.,
PureTech Ventures/ Enlight
Biosciences
Scientist, Idenix & Anadys
Pharma.
Investments: ImmuneXcite &
Lyndra.
FOCUS AREAS: therapeutics and
devices
Carl Berke, PhDPartner
Innovator & Strategy Consultant
Partner, Integral/Analysis Group
R&D Director, Polaroid & Hygeia
Founder & Director, Mass
Medical Angels
Licensing Officer, MIT
Investments: Annovation, QPID,
lifeIMAGE, Sebacia &
Syntimmune
FOCUS AREAS: materials,
devices, diagnostics,
HIT/software and chemistries
Jay KnowlesPartner
BD Executive & CEO
20+ years in business
development
CEO, X-BODY (acquired by
Juno)
BD Exec, Novartis and Vertex
Investments: Abcuro, Editas,
Denali, Keros, LTI, Quartet &
Tilos.
FOCUS AREAS: therapeutics
Roger KittermanManaging Partner
Entrepreneur & Venture
Capitalist
20+ years venture experience
Co-Founder, Mass Medical
Angels
Partner, Mi3 Venture Partners
Investments: CoStim, Adheron,
Spero, RaNA and Magenta.
FOCUS AREAS: therapeutics
![Page 4: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/4.jpg)
Barbara Fox
CEO, Tilos Therapeutics, Inc.
John Ripple
CEO, Ensemble Therapeutics
Experienced Early-Stage
Industry Leaders
Executive Leadership
Operating Experience
Business Development
Scientific Discovery
Raising Venture Capital
E I R P R O G R A M : G R O W I N G O P E R A T I O N A L E X P E R I E N C E
20+ years biotechnology experience
• CEO, Avaxia Biologics
• EIR, Oxford Bioscience
• President, Founder & CSO,
Recovery Pharmaceuticals
• Assoc. Professor of Medicine, U of
Maryland School of Medicine
PhD Chemistry, MIT
BA Chemistry, Bryn Mawr College
20+ years biopharma experience
• CEO, Permeon Biologics
• CEO, Virdante Pharmaceuticals
• CEO, Syntonix Pharmaceuticals
• BD Exec, Wyeth/Genetics Institute
• Advisor, MIT Deshpande Center
MBA, Harvard Business School
BS Mechanical Engineering, Bucknell
University
![Page 5: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/5.jpg)
P I F I N V E S T M E N T P I P E L I N E
P A R T N E R S H E A L T H C A R E S Y S T E M
Pre-clinical, clinical, post-approval and observational research
Longitudinal patient data: intervention, cost, outcomes, patient
behavior and population management
Tissue and other bio-repositories
Big Data and connected health
P R O C E S S O F T E C H N O L O G Y I N N O V A T I O N
A N D C O M P A N Y C O N C E P T I O N
Annual Pipeline
>10,000 Scientific
Publications
Annually
> 500 Invention
Disclosures
>250 Patent
Filings
>50 Qualified
Opportunities
3-5 NewCo
Investments
![Page 6: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/6.jpg)
P I F : A C T I V E P O R T F O L I O
Name Start Sector Description
Abcuro* 2016 Therapeutics Immuno-oncology and autoimmune therapy
ImmuneXcite* 2016 Therapeutics Immunotherapy platform targeting innate immune response
Keros* 2016 Therapeutics Treatment of rare muscle disorders
Lyndra* 2016 Therapeutics Extended release technology for orally administrated drugs
Magenta* 2016 Therapeutics Stem cell therapeutics platform
Tilos* 2016 Therapeutics Immunotherapy based on repression of T regs
Denali 2015 Therapeutics Neurodegenerative therapeutics
LTI 2014 Therapeutics Neurodegenerative therapies
Quartet 2014 Therapeutics Treatments for neuropathic pain
Syntimmune 2014 Therapeutics Treatment for autoimmune disorders
Spero 2013 Therapeutics Novel anti-infectives
RaNA 2011 Therapeutics RNA-based therapies
Sebacia 2010 Medical Devices Photoactivated topical treatment for acne
lifeIMAGE 2009 HIT Cloud based diagnostic image exchange
![Page 7: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/7.jpg)
P I F H A S S T R O N G S Y N D I C A T E P A R T N E R S
$1 Billion
Equity co-investment
by syndicate partners
in PIF portfolio
companies
Str
ate
gic
Part
ners
Established relationships with top tier venture capital and strategic industry partners
![Page 8: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/8.jpg)
P O R T F O L I O C O M P A N Y T H E R A P E U T I C A S S E T S -
C L I N I C A L D E V E L O P M E N T
Current Company Portfolio Company Product Late Preclinical Phase I Phase II Indication
Magenta Magenta MGTA-456Cord Blood Transplant
Medicines Company Annovation ABP-700 Anesthesia
Novartis CoStim PDR-001 Oncology
Roche Adheron RG-6125 Rheumatoid Arthritis
Syntimmune Syntimmune SYNT-001 Immunology
Denali Denali RIP1 Neurodegeneration
Novartis CoStim LAG-525 Oncology
Novartis CoStim MBG-453 Oncology
Novartis CoStim FAZ-053 Oncology
Spero Spero SPR-741 Infectious Disease
Keros Keros FOP
LTI LTI Parkinson's
Lyndra Lyndra Neuro
Quartet Quartet Pain
Translate (RaNA) Translate (RaNA) Cystic Fibrosis
![Page 9: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/9.jpg)
L I Q U I D I T Y E V E N T S
CoStim - record breaking return for an early-stage biotech company (24x if all
milestones are reached)
Editas – Market leader in CRISPR genome editing (IPO Feb 2016)
Annovation - game-changing anesthetic agent representing most significant new
technology in 30 years if approved
Company Description
Event
(Year) Acquirer / IPO
Enterprise
Value
Novel treatments for
fibrotic diseases2015 $580M
Safer Anesthesia 2015 Undisclosed
Immuno-oncology
drugs 2014 Undisclosed
Gene Editing 2016IPO (NASDAQ:
EDIT)$639M
EHR intelligence
software 2016 Undisclosed
Lysosome-based
genetic disorders2017 Undisclosed
![Page 10: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/10.jpg)
H O W T O E N G A G E W I T H P I F
• HOW TO ACCESS US: Contact us directly or work through Market Sector
Leader or Licensing Manager
• WHAT WE EXPECT: First meetings focus on science/technology, medical
need and proposed development path
• WHAT WE DON’T EXPECT: No expectation that PI will have developed
business plan or an established a team/CEO
• OUR PROCESS: Collaborative! PIF works with scientific founder(s) to build
a plan, team and investment syndicate
![Page 11: A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners …facultydevelopment.massgeneral.org/orcd/pdf/20170726… · · 2017-08-01$65 million strategic fund capitalized](https://reader038.vdocuments.site/reader038/viewer/2022110223/5ab271a27f8b9ac66c8d63a0/html5/thumbnails/11.jpg)
Partners Innovation Fund Partners HealthCare
215 First Street, Suite 500
Cambridge, MA 02142
857-307-2400
innovation.partners.org
Advancing Innovation in Health Care